Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Liabilities and Shareholders Equity (2016 - 2025)

Iradimed (IRMD) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $114.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 21.72% to $114.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $421.2 million, a 15.6% increase, with the full-year FY2024 number at $98.3 million, up 6.69% from a year prior.
  • Liabilities and Shareholders Equity was $114.7 million for Q3 2025 at Iradimed, up from $106.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $114.7 million in Q3 2025 to a low of $72.2 million in Q1 2021.
  • A 5-year average of $87.0 million and a median of $85.5 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 0.19% in 2022, then grew 21.72% in 2025.
  • Iradimed's Liabilities and Shareholders Equity stood at $82.9 million in 2021, then rose by 3.18% to $85.5 million in 2022, then rose by 7.77% to $92.2 million in 2023, then grew by 6.69% to $98.3 million in 2024, then increased by 16.68% to $114.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Liabilities and Shareholders Equity are $114.7 million (Q3 2025), $106.4 million (Q2 2025), and $101.7 million (Q1 2025).